Supporting Information

Delivery of Rapamycin by Biomimetic Peptide Nanoparticles Targeting Oxidized Low-Density Lipoprotein in Atherosclerotic Plaques

Anqi Wang[1)], Kai Yue[1,2)], Weishen Zhong[1)], Genpei Zhang[1)], Lei Wang[3)], Hua Zhang[4)], Xinxin Zhang[1,2)]*

1) School of Energy and Environmental Engineering, University of Science and Technology Beijing, Beijing 100083, China

2) Shunde Graduate School of University of Science and Technology Beijing, Shunde, Guangdong Province, 528399, China

3) CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), Beijing 100190, China

4) Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.

**Corresponding author: yuekai@ustb.edu.cn*

Figure S1. Initial configuration of the FRB and RAPA.



Figure S2. Initial configurations of the peptides and RAPA.



Figure S3. Initial configurations of SMD simulations.



Figure S4. HPLC profile and MS analyse of P1.



Integration Results

No.	Peak Name	Retention Time min	Area mAU*min	Height mAU	Relative Area %	Relative Height %	Amount n.a.
1		10.698	0.114	0.932	0.09	0.12	n.a.
2		10.872	0.155	1.233	0.12	0.15	n.a.
3		12.167	0.130	1.294	0.10	0.16	n.a.
4		12.392	0.319	2.621	0.25	0.33	n.a.
5		13.092	0.131	1.165	0.10	0.15	n.a.
6		13.303	1.878	16.822	1.50	2.10	n.a.
7		13.505	121.315	768.359	96.87	95.95	n.a.
8		14.023	0.941	6.829	0.75	0.85	n.a.
9		14.563	0.256	1.524	0.20	0.19	n.a.
Total:			**125.240**	**800.779**	**100.00**	**100.00**	



Figure S5. HPLC profile and MS analyse of P2.



Integration Results

No.	Peak Name	Retention Time min	Area mAU*min	Height mAU	Relative Area %	Relative Height %	Amount n.a.
1		13.212	0.248	1.879	0.31	0.41	n.a.
2		13.758	77.994	449.966	98.62	98.21	n.a.
3		14.107	0.425	4.537	0.54	0.99	n.a.
4		14.462	0.335	1.503	0.42	0.33	n.a.
5		14.928	0.080	0.295	0.10	0.06	n.a.
Total:			**79.081**	**458.180**	**100.00**	**100.00**	



Figure S6. HPLC profile and MS analyse of P3.



Integration Results

No.	Peak Name	Retention Time min	Area mAU*min	Height mAU	Relative Area %	Relative Height %	Amount n.a.
1		10.442	0.213	1.757	0.33	0.39	n.a.
2		10.798	60.355	424.109	95.02	94.27	n.a.
3		11.343	0.238	1.827	0.37	0.41	n.a.
4		11.570	2.710	22.188	4.27	4.93	n.a.
Total:			**63.516**	**449.881**	**100.00**	**100.00**	



Figure S7. Zeta-potential of P1, P2 and P3.



Figure S8. FTIR spectra of P1, P2 and P3.



Figure S9. Encapsulation, drug loading and drug leakage efficiencies of P1 and P2.



Figure S10. Encapsulation, drug loading and drug leakage efficiencies of P3.



Figure S11. Viability of RAW264.7/HUVEC cells.


RAW264.7
Cell viability (%)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
control
10μM
20μM
40μM
80μM
160μM


HUVEC
Cell viability (%)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
control
10μM
20μM
40μM
80μM
160μM